Merck Patent Gmbh

Merck Patent Gesellschaft MIT Beschrankter Haftung

Metabolys

Poxel S.a.s.

Albert Rolland S.a.

Merck Sante

Merck Patent Gesellschaft

Merck Patent Gesellschaft MIT Beschraenkter Haftung

Merck Patent Gesellschaft MIT

Lipha

Gérard Moinet

Daniel Cravo

Micheline R Kergoat

Didier Mesangeau

Liliane Doare

Gabriel Baverel

Gérard Botton

Annick Arbellot De Vacqueur

Caroline Leriche

Dominique Marais

Remi Nazaret

Thierry Imbert

Bernard Ferrier

Dieter Dorsch

Hans-Peter Buchstaller

Denis Carniato

Christine G Charon

Sophie Hallakou-Bozec

Annick Audet

Ansgar Wegener

Valerie Autier

Philippe Maizeray

Valérie Autier

Dominique Mariais

Catherine Kargar

Thierry Passemar

Jean-Claude Correc

Annick Arbellot De Vacueur

Rémi Nazaret

Compounds of formula (I) or their enantiomers, diastereoisomers thereof and the addition salts thereof with pharmaceutically acceptable bases or acids, for use for the prevention or treatment, preferably treatment, of NASH. 

Treatment for the non alcoholic steatohepatitis and fibrosis

The present disclosure relates to a composition including, in combination, metformin or a salt thereof, a pharmaceutically acceptable carrier or excipient and at least one compound of formula (I), or the enantiomers, diastereoisomers or pharmaceutically acceptable salts thereof. Formula (I) is as follows:  The present disclosure also relates to the use of this composition for the treatment of diseases associated with insulin resistance syndrome.

Composition and kit comprising piperazine derivatives and metformin, and use thereof in the treatment of diabetes

Disclosed herein are compounds and compositions useful in the treatment of pathologies associated with the insulin resistance syndrome (or syndrome X), in particular in the treatment of type 2 diabetes. 

Piperazine derivatives, methods for preparing same, and uses thereof in the treatment of insulin resistance

The invention relates to a compound of formula (I), where R, R, R, m, n, and Lare as defined in claim, and to the methods for preparing same, to the pharmaceutical compositions containing same, and to the uses thereof in the treatment of diseases associated with insulin resistance syndrome. 

Compounds of the formula I in which R, X and Y have the meanings indicated in Claimare inhibitors of Tankyrase, and can be employed, inter alia, for the treatment of diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation.

Substituted pyrrolo[1,2-A]pyrazin-1-ones and pyrazolo[1,5-A]pyrazin-4-ones as inhibitors of tankyrase and poly(ADP-ribose)polymerase activity

The present invention relates to combinations of triazine derivatives and of insulin sensitizers.

Combination of triazine derivatives and insulin sensitisers

Imidazole derivatives of formula (I): wherein R, R, R, A, V and W are as defined in the description,

Imidazole derivatives as fructose-1,6-bisphosphatase inhibitors and pharmaceutical compositions containing them

The invention relates to the compounds of the general formula (I): in which A, D, R, Rand X are as defined in the description,to a process for the preparation thereof and to the therapeutic use thereof in the treatment of pathologies associated with insulin resistance syndrome.

Imidazolecarboxamide derivatives as fructose-1,6-bisphosphatase inhibitors, and pharmaceutical compositions comprising same

The invention relates to the use of imidazole derivatives of the formula (1): in which A, R', R&#x2032;and R&#x2032;are as defined in the description, as AMPK activators. The invention also relates to processes for the preparation of the said compounds, to their uses for the preparation of medicaments for the treatment of insulin resistance, diabetes and related pathologies, and also obesity, and to the pharmaceutical compositions comprising them. Certain compounds of the formula (1) are novel and, in this respect, also form part of the invention.

Use of AMPK-activating imidazole derivatives, preparation process therefor and pharmaceutical compositions comprising them

The present patent application relates to novel combinations of a triazine derivative and of an insulin secretion stimulator.

Combination of triazine derivatives and insulin secretion stimulators

The present patent application relates to the use of triazine derivatives as cicatrising or angiogenic agents.

Use of triazine derivatives for the manufacture of a medicament having a cicatrising or angiogenic effect

The present invention relates to the use of a 4-oxobutanoic acid derivative for the preparation of a pharmaceutical composition for treating inflammation.

Use of 4-oxobutanoic acid derivatives in the treatment of inflammation

The invention relates to compounds of general formula (1): in which R1, R2, R3, R4, R5, A, B, D and E are as defined in Claim, and also to the preparation process therefor and the therapeutic use thereof. These compounds can be used in the treatment of pathologies associated with hyperglycaemia. 

Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes

The invention relates to the compounds of general formula (I): in which R1, R2, R3, R4, R5 and R6 are as defined in Claim These compounds can be used in the treatment of pathological conditions associated with the insulin-resistance syndrome.

Dihydro-1,3,5-triazine amine derivatives and their therapeutic uses

The present invention relates to the use of at least one compound with inhibitory activity on kynurenine 3-hydroxylase for the preparation of a medicament for the prevention and/or treatment of diabetes.

Growing community of inventors

Orsay, France

Gérard Moinet